Tyra Biosciences, Inc.

Stage 4 · Declining · week 10

As of Oct 22, 2026, Tyra Biosciences is in Stage 4, the downtrend phase, now in week 10 (since Aug 19, 2026). It closed at $20.87, 47.3% below its 52-week high and below its 200-day average, which is falling.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. More about the company

$20.87

+1.31% today

$1.4B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TYRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 22w

S4 27w

S1 13w

S2 35w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 8w → S4 12w → S1 3w → S2 11w → S3 6w → S2 22w → S3 4w → S4 27w → S1 13w → S2 35w → S3 11w → S4 9w current

Total tracked: 166 weeks across 13 stage runs.

TYRA among Biotechnology105th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…105	TYRATyra Biosciences, Inc.	Stage 4 · wk 10	83	−10.2%

vs 52W High

-47.3%

$13.99 lo$39.61 hi

47.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 10

1w13w26w

Week 10, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-30.7%

200 DMA: $30.12 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.92x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.2%

-31.9%

-43.1%

YTD

-22.1%

+41.9%

Scan Membership

Breakout Watch

Latest: 2024-06-11

4 appearances in last 60 days. First seen: 2023-02-07.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 10 · Vol 0.92x

2026-10-21S4

Wk 9 · Vol 0.71x

2026-10-20S4

Wk 9 · Vol 0.68x

2026-10-19S4

Wk 9 · Vol 0.97x

2026-10-16S4

Wk 9 · Vol 0.72x

2026-10-15S4

Wk 9 · Vol 0.44x

2026-10-14S4

Wk 8 · Vol 0.51x

2026-10-13S4

Wk 8 · Vol 0.50x

2026-10-12S4

Wk 8 · Vol 0.35x

2026-10-09S4

Wk 8 · Vol 0.68x

2026-10-08S4

Wk 8 · Vol 0.84x

2026-10-07S4

Wk 7 · Vol 0.50x

Moving averages & range

50 DMA

$23.24

200 DMA

$30.12

52W High

$39.61

52W Low

$13.99

5D Low

$18.52

Resistance levels (recent highs)

20d High

$21.98

60d High

$33.06

120d High

$37.04

250d High

$39.61

Next resistance

+5.3%

to 20d High

ROE

-45.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.5

Tyra Biosciences: quick answers

What stage is Tyra Biosciences in?

As of Oct 22, 2026, Tyra Biosciences (TYRA) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 19, 2026 and is in week 10. What the four stages mean

Is Tyra Biosciences in an uptrend?

No. Tyra Biosciences is in a Stage 4 downtrend. It trades 30.7% below its 200-day average, which is falling.

How far is Tyra Biosciences from its 52-week high?

Tyra Biosciences closed at $20.87 on Oct 22, 2026, 47.3% below its 52-week high of $39.61. Its 52-week low is $13.99.

How has Tyra Biosciences performed over the past year?

As of Oct 22, 2026, Tyra Biosciences is up 41.9% over the past year and down 22.1% so far in 2026.

Which sector and industry is Tyra Biosciences in?

Tyra Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.